Nerandomilast
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications
Management of Progressive Pulmonary Fibroses - 2025 Update
Journal: Deutsche medizinische Wochenschrift (1946)
Published: March 09, 2026
Nerandomilast in Autoimmune-Associated Interstitial Lung Diseases: Translating Evidence from Progressive Pulmonary Fibrosis Studies.
Journal: Journal of clinical medicine
Published: February 17, 2026
Evolving management of SARD-ILD : Current challenges and emerging treatment options for rheumatoid-associated interstitial lung diseases
Journal: Zeitschrift fur Rheumatologie
Published: January 26, 2026
Pathogenesis and immune regulation of rheumatoid arthritis-associated interstitial lung disease: from basic research to clinical implications.
Journal: Frontiers in immunology
Published: December 18, 2025
Nerandomilast attenuates idiopathic inflammatory myopathy-associated interstitial lung disease via inhibiting proliferation and differentiation of B cells.
Journal: Frontiers in immunology
Published: December 18, 2025
Industry payments and prescribing patterns of antifibrotic therapy for idiopathic pulmonary fibrosis in the United States.
Journal: Respiratory medicine
Published: December 16, 2025
Nerandomilast (Jascayd) for idiopathic pulmonary fibrosis.
Journal: The Medical letter on drugs and therapeutics
Published: December 15, 2025
Targeting autoimmunity: Phosphodiesterase inhibitors as immunomodulators-a review of current insights and future direction.
Journal: Autoimmunity reviews
Published: December 13, 2025
Network meta-analysis of pharmacological treatments for idiopathic pulmonary fibrosis: evaluating effects on lung function.
Journal: Frontiers in pharmacology
Published: December 06, 2025
Most Promising Emerging Therapies for Pulmonary Fibrosis: Targeting Novel Pathways.
Journal: Biomedicines
Published: December 03, 2025
Last Updated: 04/28/2026